Additionally, it is worth noting the small sample sizes in individual studies and the absence of randomized controlled trials examining the long-term impact of IL-17 and IL-23 inhibitors on tumor evaluation, contributing to an overall lack of statistical power. This evidence concerns the gene IL17A and neoplasm.